TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15198887

Group type: EXPERIMENTAL
Intervention: Healthcare professionals' awareness of ADR reporting
Number of subjects: 1653

Group type: EXPERIMENTAL
Intervention: Healthcare professionals' understanding of ADRs
Number of subjects: 1653

Group type: EXPERIMENTAL
Intervention: Actual reporting of ADRs
Number of subjects: 1653

Group type: EXPERIMENTAL
Intervention: Reporting channels used by healthcare professionals
Number of subjects: 1653

Group type: EXPERIMENTAL
Intervention: Reasons for not reporting ADRs
Number of subjects: 1653
Study: 11482924

Group type: EXPERIMENTAL
Intervention: Sotalol (80 mg b.i.d.)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Bisoprolol (5 mg x day(‐1))
Number of subjects: 128
Study: 9757602

Group type: EXPERIMENTAL
Intervention: High-salt diet (21.0 g NaCl)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normal-salt diet (approximately 5.6 g NaCl)
Number of subjects: 6
Study: 7831452

Group type: EXPERIMENTAL
Intervention: Novel nonsedating compound (dose not specified)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Multiple-rater procedure (MRP)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Single-rater procedure (SRP)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study: 3242576

Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs (ACE inhibitors, calcium antagonists, direct vasodilators, alpha‐adrenoceptor blocker, beta‐adrenoceptor blocker)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Antihypertensive agents (four types)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 30263038

Group type: EXPERIMENTAL
Intervention: Green cardamom (GC) - 2 capsules of 500 mg three times per day for 3 months
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 27353989

Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation (PNF) techniques
Number of subjects: 63

Group type: COMPARATOR
Intervention: Traditional Prosthetic Strength Training (TPT)
Number of subjects: 63
Study: 24325269

Group type: EXPERIMENTAL
Intervention: CS2 (second conditioning stimulus)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: CS1 (first conditioning stimulus)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: CS1 and CS2
Number of subjects: 19
Study: 23814179

Group type: EXPERIMENTAL
Intervention: Fitwits intervention (training for physicians)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no Fitwits training)
Number of subjects: 86
Study: 20523304

Group type: EXPERIMENTAL
Intervention: Internet group (n = 34)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Information only control group (n = 31)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Internet group compliers
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Per-protocol analysis
Number of subjects: 65
Study: 19401661

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg intravenously after induction of anaesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 30
Study: 16125823

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) markers for amyloid beta deposits and tau pathology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longitudinal hippocampal volume measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CSF levels of hyperphosphorylated tau and isoprostane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Memory measures and MRI-hippocampal volume evaluations
Number of subjects: 0
Study: 15590252

Group type: EXPERIMENTAL
Intervention: Alfentanil (1 mg)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.01 mg
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.02 mg
Number of subjects: 175

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 175
Study: 11713062

Group type: EXPERIMENTAL
Intervention: Initial trabeculectomy
Number of subjects: 607

Group type: COMPARATOR
Intervention: Initial medical therapy
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Surgical patients
Number of subjects: 607
Study: 7490173

Group type: EXPERIMENTAL
Intervention: ST200 at 1 g/die
Number of subjects: 94

Group type: COMPARATOR
Intervention: ST200 at 0.5 g/die
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 2208182

Group type: EXPERIMENTAL
Intervention: CQA 206‐291 (5‐30 mg/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 517068

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other marketed bronchodilators (clenbuterol, epinephrine, fenoterol, hexoprenaline, isoprenaline, metaproterenol, reproterol, salbutamol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terbutaline and other adrenoceptor agonists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vagolytics (atropine, ipratropium bromide, AA 28‐263)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Theophylline ethylenediamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined substance drug
Number of subjects: 0
Study: 31155655

Group type: EXPERIMENTAL
Intervention: Smartphone-assisted counselling application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28114587

Group type: COMPARATOR
Intervention: Transcorneal electrical stimulation (TES) at 200% of individual electrical phosphene threshold (EPT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Transcorneal electrical stimulation (TES) at 150% of individual electrical phosphene threshold (EPT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 52
Study: 25669730

Group type: EXPERIMENTAL
Intervention: Eltoprazine 5 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Eltoprazine 7.5 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 24860934

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 28
Study: 22424441

Group type: EXPERIMENTAL
Intervention: Dexamethasone (1.0 mg)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (healthy controls, n=33)
Number of subjects: 83
Study: 21058203

Group type: EXPERIMENTAL
Intervention: Low-fat diet counseling
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Reduced carbohydrate diet counseling
Number of subjects: 40
Study: 17620068

Group type: COMPARATOR
Intervention: Placebo challenge
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Active food challenge
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Statistical model
Number of subjects: 105
Study: 15677734

Group type: EXPERIMENTAL
Intervention: Recombinant human TNF-alpha (n = 8)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Recombinant human IL-6 (n = 6)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle (n = 6)
Number of subjects: 20
Study: 12010887

Group type: EXPERIMENTAL
Intervention: Biennial Haemoccult (FOB) test kit
Number of subjects: 152850

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 152850

Group type: EXPERIMENTAL
Intervention: Screening acceptance
Number of subjects: 152850
Study: 10452229

Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Glycine (placebo)
Number of subjects: 23
Study: 8690814

Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron (oral and intravenous)
Number of subjects: 12
Study: 1947367

Group type: EXPERIMENTAL
Intervention: Cefaclor (500 mg tds) for 7 days
Number of subjects: 51

Group type: COMPARATOR
Intervention: Amoxycillin (500 mg tds) for 7 days
Number of subjects: 51
Study: 6361318

Group type: EXPERIMENTAL
Intervention: KS-R1 (ampicillin rectal suppository) at a dose of 125 mg X 4/day for 7 days
Number of subjects: 166

Group type: COMPARATOR
Intervention: Oral form of ampicillin (ABPC) at the same dosage of 125 mg X 4/day for 7 days
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: KS-R1 (ampicillin rectal suppository)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Oral form of ampicillin (ABPC)
Number of subjects: 166
Study: 30945979

Group type: EXPERIMENTAL
Intervention: Single-Port Laparoscopic Appendectomy (SPLA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Three-Port Laparoscopic Appendectomy (3PLA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 50
Study: 28986670

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) administered intravenously for three consecutive days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Methylprednisolone administered intravenously for three consecutive days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Observation (no treatment)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Late treatment (>3 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Initial BCVA of no light perception (NLP)
Number of subjects: 100
Study: 27003141

Group type: EXPERIMENTAL
Intervention: Group IPT adapted for perinatal loss
Number of subjects: 50

Group type: COMPARATOR
Intervention: Coping with Depression (CWD)
Number of subjects: 50
Study: 24625546

Group type: EXPERIMENTAL
Intervention: Real rTMS treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham rTMS treatment
Number of subjects: 10
Study: 22367073

Group type: EXPERIMENTAL
Intervention: Direct fed microbial (DFMD; 0.3%)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Standard control starter diet (CSD)
Number of subjects: 192
Study: 19169442

Group type: EXPERIMENTAL
Intervention: 5% sodium hypochlorite applied for 1 minute after acid conditioning of tooth surfaces
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (teeth on the left side of the jaw)
Number of subjects: 4
Study: 17505047

Group type: EXPERIMENTAL
Intervention: Self-regulation, telephone counseling intervention
Number of subjects: 808
Study: 15102866

Group type: EXPERIMENTAL
Intervention: Levofloxacin 1000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levofloxacin 1500 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levofloxacin (various doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levofloxacin (1500 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12066701

Group type: EXPERIMENTAL
Intervention: Excite dual‐cured bonding agent self‐activated by an experimental microbrush in combination with MultiLink resin cement
Number of subjects: 30

Group type: COMPARATOR
Intervention: Excite light‐cured bonding agent in combination with Variolink II resin cement
Number of subjects: 30

Group type: COMPARATOR
Intervention: One‐step bonding system in combination with Dual Link resin cement
Number of subjects: 30
Study: 9836021

Group type: EXPERIMENTAL
Intervention: d-amphetamine (0.25 mg/kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 9860471

Group type: EXPERIMENTAL
Intervention: Day-care laparoscopic cholecystectomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clinical observation after laparoscopic cholecystectomy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Day-care group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clinical observation group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Day-care patients
Number of subjects: 80
Study: 2695819

Group type: EXPERIMENTAL
Intervention: Exfoliative cytology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional bioptic examination
Number of subjects: 0
Study: 16039

Group type: EXPERIMENTAL
Intervention: 3 to 6 mg lorazepam daily for four weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31375335

Group type: EXPERIMENTAL
Intervention: Second hand smoke (SHS) exposure
Number of subjects: 910
Study: 29670416

Group type: EXPERIMENTAL
Intervention: Intravenous Oxycodone
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intravenous Morphine
Number of subjects: 66
Study: 26032791

Group type: EXPERIMENTAL
Intervention: Self-reported staging for the goal of eating a low-fat diet
Number of subjects: 2057

Group type: EXPERIMENTAL
Intervention: Self-assessed motivation and food frequency measures
Number of subjects: 2057
Study: 23927572

Group type: EXPERIMENTAL
Intervention: Baker's yeast beta-glucan (BG)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo (rice flour)
Number of subjects: 242
Study: 22114294

Group type: EXPERIMENTAL
Intervention: High arousing emotional stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low arousing neutral pictures
Number of subjects: 0
Study: 18938119

Group type: EXPERIMENTAL
Intervention: Resorbable poly[(R)‐3‐hydroxybutyrate] (PHB)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Microsurgical epineural end‐to‐end suturing
Number of subjects: 12
Study: 16974197

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 15205601

Group type: COMPARATOR
Intervention: PEG‐IFN‐alpha (6 microg/kg/week s.c. for 8 weeks, then 3 microg/kg/week s.c. maintenance)
Number of subjects: 40

Group type: COMPARATOR
Intervention: PEG‐IFN‐alpha
Number of subjects: 40
Study: 11258112

Group type: EXPERIMENTAL
Intervention: DDD/AMC mode
Number of subjects: 48

Group type: COMPARATOR
Intervention: DDD mode
Number of subjects: 48
Study: 9249634

Group type: EXPERIMENTAL
Intervention: Gingival retraction cord (aluminum sulfate-impregnated)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Gingival retraction cord (non-impregnated)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Root planing only (control group)
Number of subjects: 75
Study: 8519045

Group type: EXPERIMENTAL
Intervention: Probucol (750 mg or 1000 mg daily)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Dipyridamole (150 mg daily)
Number of subjects: 67
Study: 3755127

Group type: EXPERIMENTAL
Intervention: Bacterial lysate
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 29847470

Group type: EXPERIMENTAL
Intervention: 8% topical capsaicin patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 27842943

Group type: EXPERIMENTAL
Intervention: Raloxifene 120mg/day
Number of subjects: 30
Study: 24630545

Group type: EXPERIMENTAL
Intervention: Group exercise class
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Individual physiotherapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Home exercises alone
Number of subjects: 75
Study: 23075701

Group type: EXPERIMENTAL
Intervention: 200 mg twice a day for 7 days (group A)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 300 mg twice a day for 7 days (group B)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 400 mg twice a day for 3 days each week for 2 weeks (group C)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 105
Study: 19587296

Group type: EXPERIMENTAL
Intervention: Punishment severity for perpetrators of hate crimes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Victim blame
Number of subjects: 0

Group type: COMPARATOR
Intervention: Punishment severity for perpetrators of other types of crimes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Victim and perpetrator blame
Number of subjects: 0
Study: 19088469

Group type: EXPERIMENTAL
Intervention: Formula with Lactobacillus johnsonii (La1)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control formula without Lactobacillus johnsonii (La1)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Breastfed infants
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: All infants receiving La1
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: All groups (La1, control formula, breastfed)
Number of subjects: 71
Study: 16181164

Group type: EXPERIMENTAL
Intervention: FAME program (1-hour sessions, three sessions/week, for 19 weeks)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Seated upper extremity program (control group)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: FAME program
Number of subjects: 63
Study: 12687927

Group type: EXPERIMENTAL
Intervention: Drug I (propafenone, sotalol, disopyramide)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Drug II (second antiarrhythmic agent)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Drug III (amiodarone)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Amiodarone during loading period
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Amiodarone after repeated CV
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Long-term amiodarone treatment
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Overall effect of amiodarone
Number of subjects: 104
Study: 10419086

Group type: EXPERIMENTAL
Intervention: DHA-rich oil capsules (1.5-1.8 g DHA/d)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control oil capsules (97% soybean oil + 3% fish oil)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: DHA-rich oil capsules (2 months)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control oil capsules (2 months)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: DHA-sufficient diet (4 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: DHA-deficient diet (4 weeks)
Number of subjects: 42
Study: 7539874

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 40
Study: 2193119

Group type: EXPERIMENTAL
Intervention: 12-week chemohormonal treatment (CMFVP plus AT)
Number of subjects: 222

Group type: COMPARATOR
Intervention: 36-week chemohormonal treatment (CMFVP)
Number of subjects: 222
Study: 4935627

Group type: EXPERIMENTAL
Intervention: Glycyrrhizinic-acid-reduced liquorice 760 mg thrice daily for six weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 30975612

Group type: EXPERIMENTAL
Intervention: EUS-FNB + ROSE
Number of subjects: 800

Group type: COMPARATOR
Intervention: EUS-FNB alone
Number of subjects: 800
Study: 28234199

Group type: EXPERIMENTAL
Intervention: In-person or Internet formats of administration for SES-SFP with men
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: In-person or Internet formats of administration for SES-SFV with women
Number of subjects: 569

Group type: COMPARATOR
Intervention: SES-SFV with men
Number of subjects: 569

Group type: COMPARATOR
Intervention: SES-SFP with women
Number of subjects: 569
Study: 25830489

Group type: EXPERIMENTAL
Intervention: PHiD-CV and DTPa
Number of subjects: 360

Group type: COMPARATOR
Intervention: DTPa alone
Number of subjects: 360
Study: 22895371

Group type: EXPERIMENTAL
Intervention: High-load (HL) resistance exercise (70% peak torque)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low-load (LL) resistance exercise (20% peak torque)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low-load blood flow-restricted (LL(BFR)) resistance exercise (20% peak torque with an occlusive cuff inflated to 180 mm Hg)
Number of subjects: 8
Study: 22089991

Group type: EXPERIMENTAL
Intervention: Sonographic image-guided injection
Number of subjects: 94

Group type: COMPARATOR
Intervention: Conventional palpation-guided anatomic landmark injection
Number of subjects: 94
Study: 19558483

Group type: EXPERIMENTAL
Intervention: Manual oral brushing plus 0.12% chlorhexidine oral rinse administered twice per day
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Daily manual oral brushing and upright feeding positioning
Number of subjects: 52
Study: 16794647

Group type: EXPERIMENTAL
Intervention: Sexuality education in schools
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Perceptions of young people's sexual activity
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Teaching of contraception and safe abortion in schools
Number of subjects: 250
Study: 15155893

Group type: EXPERIMENTAL
Intervention: Screen-film mammography (SFM)
Number of subjects: 25263

Group type: COMPARATOR
Intervention: Full-field digital mammography (FFDM)
Number of subjects: 25263
Study: 11231036

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) at a frequency of 0.2 Hz and intensity of 90% of motor threshold, delivered in four daily sessions with a train of 70 stimuli over 350 s
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study: 9406983

Group type: EXPERIMENTAL
Intervention: Atenolol 12.5 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atenolol 37.5 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8218987

Group type: EXPERIMENTAL
Intervention: Infusion of 0.2 micrograms/kg ceruletide
Number of subjects: 105

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 105
Study: 3619095

Group type: EXPERIMENTAL
Intervention: 0.86 mg/kg nalbuphine
Number of subjects: 16

Group type: COMPARATOR
Intervention: 0.17 mg/kg butorphanol
Number of subjects: 16
Study: 29048132

Group type: EXPERIMENTAL
Intervention: US-guided rhomboid major muscle injection
Number of subjects: 65

Group type: COMPARATOR
Intervention: US-guided trapezius muscle injection
Number of subjects: 65
Study: 27223304

Group type: EXPERIMENTAL
Intervention: Paleolithic diet (n = 22)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Paleolithic diet
Number of subjects: 39

Group type: COMPARATOR
Intervention: Australian Guide to Healthy Eating (AGHE) diet (n = 17)
Number of subjects: 39
Study: 23406268

Group type: EXPERIMENTAL
Intervention: 4 implants
Number of subjects: 66

Group type: COMPARATOR
Intervention: 6 implants
Number of subjects: 66
Study: 23536140

Group type: EXPERIMENTAL
Intervention: On-site rapid HIV testing at probation/parole office
Number of subjects: 1263

Group type: COMPARATOR
Intervention: Referral for rapid HIV testing off site at a community HIV testing clinic
Number of subjects: 1263
Study: 20463287

Group type: EXPERIMENTAL
Intervention: 1.5 T DWI
Number of subjects: 135

Group type: COMPARATOR
Intervention: 3.0 T DWI
Number of subjects: 135
Study: 18646713

Group type: EXPERIMENTAL
Intervention: Bilateral intercostal nerve protection (Group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Unilateral intercostal nerve protection (Group U)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard posterolateral thoracotomy (Group C)
Number of subjects: 60
Study: 16902771

Group type: EXPERIMENTAL
Intervention: Alcohol (0.6 g/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32